Morphosys jumps pre-market as FDA approves antibody drug

FRANKFURT (Reuters) - Shares in Morphosys jumped 11 percent in pre-market trade on Friday after a licensee won U.S. approval for psoriasis drug guselkumab, bringing the German biotech group a step closer to launching its first antibody drug onto the market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news